YOUR PRIVACY MATTERS

By submitting this request you are opting in to receive our emails. Each email we send you will include the option to opt out of receiving future mailings.

View our privacy policy.

Developments in Clinical Trials reports offer expert reviews of the trends and scientific developments that shape the clinical trial landscape. These insightful reviews are based on the strategic and scientific clinical data from Thomson Reuters Cortellis™ Clinical Trials Intelligence.

This edition aims to emphasize the value and use of clinical study results in the context of precision medicine and molecular diagnostics as well as to examine potential risks involved with under reporting of trial results. In addition, the role clinical study reporting has in advancing the current standard of care in clinical practice, and in human health overall.

This report also reflects on clinical trials presented at the 64th Liver Meeting 2013 in Washington D.C.
  • Emerging therapies for hepatitis C Virus infection
  • Hepatitis C Virus clinical trials, displayed favorable safety and pharmacokinetic results and clear indication of therapeutic benefits with the following inhibitors:
    • Ns3 protease inhibitors grazoprevir (merck), asunaprevir (bristol-myers squibb), and vedroprevir (Gilead)
    • Ns5a protein inhibitor elbasvir (mk-8742; merck)
    • Ns5b polymerase inhibitors vX-135 (vertex pharmaceuticals)
    • Gs-9669 (Gilead) 
    • Nucleocapsid p7 protein inhibitor bit-225 (biotron)


Missed the last issue? Click here to view the complete set of back issues for the Pharma Matters reports.

You may also be interested in....

The Ones to Watch

Quarterly review of the most promising drugs reaching the market and moving between clinical trials.
Click here
Spotlight On...
Expert therapy area review of the key market players and deals highlights for leading areas of industry investment and development.
Click here